Kingsoft Cloud Announces Unaudited Third Quarter 2025 Financial Results
Financial Performance: Kingsoft Cloud reported a 31.4% year-over-year revenue growth for Q3 2025, reaching RMB2,478 million, with significant contributions from public cloud services and AI-related customers.
Profitability Improvement: The company achieved a turnaround in adjusted operating profit to RMB15.4 million and adjusted net profit of RMB28.7 million, compared to losses in the same quarter last year.
AI Integration and Growth: Kingsoft Cloud emphasized the strategic integration of AI with cloud services, leading to a 120% year-over-year growth in AI gross billing, and a 83.8% increase in revenue from its collaboration with the Xiaomi-Kingsoft ecosystem.
Cost Management: Operating expenses decreased significantly by 63.6% year-over-year, contributing to improved profitability, while the gross margin slightly declined due to higher costs associated with AI business expansion.
Trade with 70% Backtested Accuracy
Analyst Views on KC
About KC
About the author

- Record Revenue Growth: Kingsoft Cloud achieved a quarterly revenue of RMB 2.76 billion, marking a 22% year-over-year increase, which underscores the company's robust performance in the cloud services market and strengthens its competitive position.
- Public Cloud Services Surge: Revenue from public cloud services reached RMB 1.9 billion, a 35% year-over-year growth, reflecting strong demand for intelligent computing services, which is expected to drive future revenue increases.
- AI Business Expansion: The gross billing from the AI business hit RMB 926 million, a staggering 95% year-over-year increase, contributing 49% of public cloud services revenue, indicating the company's rapid expansion and market potential in the AI sector.
- Improved Profitability: The adjusted gross margin stood at 17.1%, with an adjusted operating margin of 2.0%, achieving operational profitability for two consecutive quarters, demonstrating positive progress in cost control and profitability enhancement.
- Earnings Performance: Kingsoft Cloud reported a Q4 GAAP EPS of -$0.01, beating market expectations by $0.11, indicating positive signals in the company's recovery of profitability.
- Revenue Growth: The total revenue reached $394.9 million, reflecting a 29.1% year-over-year increase, with public cloud service revenues at RMB 1,902.4 million (approximately $272.0 million), showcasing strong market demand.
- Enterprise Cloud Services: Revenue from enterprise cloud services was RMB 859.0 million (approximately $122.8 million), marking a 4.5% increase from the same quarter in 2024 and an 18.4% rise from the previous quarter, demonstrating sustained demand from enterprise clients for cloud services.
- EBITDA Metrics: Non-GAAP EBITDA stood at RMB 785.2 million (approximately $112.3 million), up 118.3% year-over-year, although it decreased by 5.0% from the previous quarter; however, the EBITDA margin of 28.4% significantly improved from 16.1% in the same quarter of 2024, indicating enhancements in cost control and profitability.
- Surge in Market Demand: The usage of OpenClaw in China has surpassed that in the U.S., indicating a strong domestic demand for this open-source AI assistant, which is driving local tech companies to develop related applications and is expected to enhance market competitiveness.
- Tencent Product Launch: Tencent has launched a full suite of AI products based on OpenClaw, dubbed 'Lobster Special Forces,' compatible with its super app WeChat, aiming to attract more users and strengthen its leadership position in the AI market.
- Government Support Policies: Local governments in Shenzhen and Hefei have proposed funding support of up to 10 million yuan to encourage companies to develop applications based on OpenClaw, demonstrating a strong commitment to promoting AI technology development.
- Installation Convenience Improvement: To reduce the installation complexity of OpenClaw, companies like ByteDance and Tencent have introduced simplified versions and on-site installation services, which are expected to attract more non-technical users and further expand the user base.
- Earnings Release Schedule: Kingsoft Cloud is set to announce its unaudited financial results for Q4 and FY2025 on March 25, 2025, before the U.S. market opens, which is expected to provide investors with critical performance data to assess the company's future growth potential.
- Conference Call Timing: Management will host an earnings conference call on March 25, 2025, at 8:15 AM U.S. Eastern Time (8:15 PM Beijing/Hong Kong Time), aimed at sharing financial performance and future strategies, thereby enhancing transparency and investor confidence.
- Registration Details: Participants must preregister via a designated link to receive dial-in numbers, event passcodes, and unique access PINs, ensuring a smooth conference experience and improving participant engagement.
- Live Webcast and Archive: The conference will be available via live and archived webcast on the company's investor relations website, allowing investors who cannot attend in real-time to review the meeting content, further enhancing information accessibility and transparency.
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.










